Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

INDIANAPOLIS , Feb. 21, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 43rd Annual Health Care Conference on Monday, March 6, 2023. Mike Mason, executive vice president and president, Lilly Diabetes and Obesity, will participate in a fireside chat at 1:30 p.m.

Lilly to Participate in Cowen's 43rd Annual Health Care Conference

Shares of this drugmaker have trounced the S&P 500 index in the last decade.

Is This Supercharged Growth Stock a Buy?

Eli Lilly and Company is a fast-growing and promising leading pharmaceutical company. Eli Lilly's shares are expensive now, trading for almost 40 times future earnings.

Eli Lilly Is Still Overvalued But Should Be On Your Watchlist

The Eli Lilly and Company diabetes upstart was on fewer formularies than reported. Less coverage meant lower Eli Lilly and Company sales, contributing to a revenue miss in Q4.

Eli Lilly: Mounjaro Needs To Catch Up In 2023

Apple

Amazon

Alphabet

Microsoft

NVIDIA

UnitedHealth Group

Exxon Mobil

Phil Gross and Robert Atchinson founded Adage Capital Partners in 2001. Gross was initially a healthcare and retail analyst at the Harvard Management Company (HMC), and later became a partner at HMC.

Top 10 Holdings of Phil Gross and Robert Atchinson

Eli Lilly and Co (NYSE:LLY ) SVB Securities Global Biopharma Conference February 16, 2023 12:00 PM ET Company Participants Ilya Yuffa - SVP & President, Lilly International Conference Call Participants David Risinger - SVB Securities David Risinger Great. Good morning, everybody.

Eli Lilly and Co (LLY) SVB Securities Global Biopharma Conference Transcript

Retailers CVS Health, Walgreens and Kroger have announced new initiatives to provide clinical trial enrollment and follow-up services in their pharmacy clinics.

Eli Lilly recruits Black patients for Alzheimer trial as drugmakers seek more diversity in clinical studies

Abbott Labs

CVS Health

Investor sentiment has improved this year on expectations of less-aggressive interest rate hikes by the Federal Reserve to tame inflation. However, the ongoing macro uncertainty continues to create confusion about which sectors or companies to invest in.

Which Healthcare Stock Is a Better Pick in 2023?

Lilly offers its human insulin API at reduced price to IABL to support insulin production in Bangladesh INDIANAPOLIS and DHAKA, Bangladesh , Feb. 13, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will supply its active pharmaceutical ingredient (API) for human insulin at a reduced price to International Agencies (Bangladesh) Ltd. (IABL) in an effort to increase patient access and improve affordability for high-quality insulin for nearly one million people living with diabetes in Bangladesh by 2030.

Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh

Axsome Therapeutics

Vertex Pharmaceuticals

Maybe there's no such thing as a sure thing. But these stocks could come close.

3 Surefire Growth Stocks You Can Buy Right Now

Bristol-Myers

Merck

Pfizer

Given enough time, stock in pharmaceutical giants has yielded life-altering gains. Because of its popular and widely distributed COVID-19 vaccine, Pfizer has sparked more controversy than other stocks in its sector.

Big Pharma's Big Gains

Aflac

Albemarle

Caterpillar

Chevron

NextEra Energy

Philip Morris

Dividend stocks pay a portion of their earnings to shareholders. Payments are usually made on a regular basis, quarterly, monthly, or annually, and provide a steady stream of income.

The 7 Best Dividend Stocks to Buy for February 2023

INDIANAPOLIS , Feb. 7, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the SVB Securities Global Biopharma Conference on Thursday, Feb. 16, 2023. Ilya Yuffa, executive vice president and president, Lilly International, will participate in a virtual fireside chat at 12 p.m.

Lilly to Participate in SVB Securities Global Biopharma Conference

Amgen

Exact Sciences

Gilead Sciences

GlaxoSmithKline

Immunocore Holdings

Moderna

Regeneron Pharmaceuticals

The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Moderna Inc. (NASDAQ: MRNA), among others.

Is Biotech Immunocore About To Make A 25% Price Move?

AbbVie

Disney

Johnson & Johnson

Tesla

The stock market finished January on a positive note. This is a good sign for investors, who incurred huge losses last year.

5 Best and Worst Performing Mega-Cap Stocks in January 2023

INDIANAPOLIS , Feb. 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Oncology Conference on Thursday, Feb. 9, 2023. Jacob Van Naarden, executive vice president and CEO, Loxo@Lilly and David Hyman, M.D.

Lilly to Participate in Guggenheim Oncology Conference

While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Lilly (LLY) Reports Q4 Earnings: What Key Metrics Have to Say

Eli Lilly's (LLY) earnings surpass fourth-quarter estimates while sales slightly miss the mark. The company raises its EPS guidance for 2023.

Lilly (LLY) Beats on Q4 Earnings, Lags on Sales, Raises '23 View

Eli Lilly and Company (NYSE:LLY ) Q4 2022 Earnings Conference Call February 2, 2023 10:00 AM ET Company Participants Joe Fletcher - Senior Vice President of Investor Relations Dave Ricks - Chairman & Chief Executive Officer Anat Ashkenazi - Chief Financial Officer Dan Skovronsky - Chief Scientific & Medical Officer Anne White - President, Lilly Neuroscience Ilya Yuffa - President, Lilly International Lilly Mike Mason - President, Lilly Diabetes Patrik Jonsson - President of Lilly Immunology & Lilly USA Conference Call Participants Colin Bristow - UBS Chris Schott - JPMorgan Seamus Fernandez - Guggenheim Geoff Meacham - Bank of America Tim Anderson - Wolfe Research Terence Flynn - Morgan Stanley Steve Scala - Cowen Louise Chen - Cantor Chris Shibutani - Goldman Sachs Umer Raffat - Evercore Mohit Bansal - Wells Fargo Evan Seigerman - BMO Trung Huynh - Credit Suisse Carter Gould - Barclays Andrew Baum - Citi Robyn Karnauskas - Truist Securities Operator Ladies and gentlemen, thank you for standing by. And welcome to the Lilly Q4 2022 Earnings Conference Call.

Eli Lilly and Company (LLY) Q4 2022 Earnings Call Transcript

Eli Lilly's LLY, -5.65% new Type 2 diabetes treatment Mounjaro may be in high demand, but the drug had a wobbly fourth quarter, with sales coming in far below Wall Street's expectations.

Lilly's ambitious diabetes drug Mounjaro fails to impress in the fourth quarter

Novo Nordisk

Novo Nordisk and Eli Lilly are both working to ramp up capacity and insurance coverage for anti-obesity drugs.

Why Obesity-Drug Makers Just Lost Weight

Lilly (LLY) delivered earnings and revenue surprises of 14.21% and 0.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) Q4 Earnings Surpass Estimates

Eli Lilly reported lighter-than-expected fourth-quarter sales Thursday, but raised its earnings outlook. LLY stock toppled.

Eli Lilly Sinks On Mixed Earnings Report, But Boosts 2023 Earnings Outlook

The pharmaceutical company said quarterly revenue fell 9% to $7.30 billion.

Eli Lilly Posts 9% Sales Drop on Covid-Treatment Decline

Eli Lilly & Co.'s LLY, -0.46% stock fell 2.3% before market open Thursday after the biopharmaceutical giant's fourth-quarter revenue came in below analysts' expectations. The company reported net income of $1.938 billion, or $2.14 a share, up from net income of $1.726 billion, or $1.90 a share, in the year-earlier period.

News for Eli Lilly Stock (LLY)